Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER: Phase 1a/1b Study of Imlunestrant (LY3484356) Alone and in Combination in ER+ Advanced Cancers (Japan)
jRCT2031200271Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of imlunestrant in breast cancer, endometrioid adenocarcinoma and Non-hematologic malignancy (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with dose-limiting toxicities and DLT-equivalent toxicities. Started Dec 2020; status: recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancerendometrioid adenocarcinomaNon-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031200271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200271.